Navigation Links
12-month ATLANTA trial data show sustained benefit of Catania Stent
Date:10/14/2008

WASHINGTON, Oct. 13 -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.

The ATLANTA Trial is a first-in-man (FIM), prospective, single center, non-randomized, single-arm study involving 55 patients (76 lesions) treated with the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F surface modification for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova BioSciences, Inc., maker of the CATANIA™ stent.

At 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028 struts) by investigators using Optimal Coherence Tomography at baseline and again at 6-month follow-up in a subset of 15 randomly selected patients revealed complete endothel
'/>"/>

Contact: David Patti
dpatti@storchmurphy.com
908-276-0777
The Storch Murphy Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DHS Begins Collecting 10 Fingerprints From International Visitors at Hartsfield-Jackson Atlanta International Airport
2. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
3. Vitamin E trials fatally flawed
4. Research team says extraterrestrial impact to blame for Ice Age extinctions
5. Trial seeks genetic fingerprint for predicting drug effectiveness
6. The industrial space age
7. Contrast agent trials in swine
8. Small-scale fishing in Mexico rivals industrial fisheries in accidental turtle deaths
9. Study of African traditional medicine will begin world-first clinical trial
10. New model revises estimates of terrestrial carbon dioxide uptake
11. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... meaning and are made with the expectation of specific ... from the University of St. Andrews in the UK. ... significant step forward with the authors, new systematic approach ... non-humans, applied here to a group of orangutan gestures. ...
... burgeon in the atmosphere causing the Earth,s climate to warm, ... gas from the atmosphere and store it where it can ... of Iceland has been studying the possibility of sequestration of ... findings today to several thousand geochemists from around the world ...
... the College of Engineering at the University of Miami ... 25 years to enhancing IEEE,s image and improving the ... being honored with the 2010 IEEE Richard M. Emberson ... technology for humanity. , "I am deeply honored by ...
Cached Biology News:Signal like you mean it 2Storing carbon dioxide deep underground in rock form 2Dean of the UM College of Engineering to receive 2010 IEEE Richard M. Emberson Award 2Dean of the UM College of Engineering to receive 2010 IEEE Richard M. Emberson Award 3
(Date:4/29/2015)... ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial statements ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , 1,703 ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... -- Cambrex Corporation (NYSE: CBM ) announced that first ... 1, 2015 before the market opens. , ... conference call to discuss the financial results. First Quarter 2015 ... Friday, May 1, 2015 at 8:30 a.m. Eastern Time ... International  Passcode:  7993632 Dial-in Replay: , ...
(Date:4/29/2015)... Poway, CA (PRWEB) April 29, 2015 ... proud to announce that its regenerative stem cell therapy ... founded in 2002, seeking to discover a successful treatment ... ligaments. , In 2003 VetStem signed a worldwide exclusive ... veterinary application, and the first horse was treated in ...
(Date:4/29/2015)... , April 29, 2015 /CNW/ - Northern Biologics Inc., ... Ventures, today announced an exclusive, strategic collaboration with ... Biologics received a US$30 million upfront cash payment. ... develop first-in-class therapeutic antibodies, and will have the ... the advancement of its portfolio. ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Evaluable Patients Had Confirmed Partial Responses (25%); ... Antonio Breast Cancer Symposium, HAYWARD, Calif., Dec. ... today announced that its Hsp90 inhibitor,tanespimycin, demonstrated meaningful ... in patients with HER2-positive metastatic breast cancer,when administered ...
... Global Biotechnology Company Adopts Pharsight,s Groundbreaking ... Automation Software, ... ), a leading provider of software and strategic,services for optimizing clinical ... purchased WinNonlin AutoPilot.,This sale marks Pharsight,s third new customer win since ...
... New Deal Provides a Further Opportunity for OGeS ... Sciences (UK) Ltd "OGeS" announces today that it ... discover, develop and,commercialise novel therapeutic antibodies for the ... to further strengthen its pipeline,of fully human therapeutic ...
Cached Biology Technology:Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 2Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 3Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 4Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 5Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 2Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 3Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
... SYBR Green I nucleic acid gel stain ... that has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... acid stain has also found uses in capillary ...
... acid gel stain has bright fluorescence when bound ... it ideal for detecting dsDNA in gels using ... Green I nucleic gel acid stain has ... assays and bandshift assays. One mL stains 100 ...
... In 1959, McCoy and his ... requirements for in vitro cultivation ... studies were performed using,Basal Medium ... create a new medium known ...
... advanced protein cross-linking techniques are defined by ... Shan S. Wong. This valuable hardcover guide ... and current application references. More than 300 ... cross-linking and conjugate preparation from selection ...
Biology Products: